Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$3.09 USD
+0.15 (5.10%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.10 +0.01 (0.32%) 7:08 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
FATE 3.09 +0.15(5.10%)
Will FATE be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for FATE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FATE
Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report?
All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy
FATE: What are Zacks experts saying now?
Zacks Private Portfolio Services
FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
Eyenovia, Inc. (EYEN) Reports Q2 Loss, Misses Revenue Estimates
Other News for FATE
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
Fate Therapeutics’ Promising Outlook: Buy Rating on Innovative Cell Therapy Programs FT819 and FT522
Fate Therapeutics (FATE) Gets a Hold from Stifel Nicolaus
Fate Therapeutics: Hold Rating Amidst Steady Q2 Financials and Clinical Progress
Wedbush Reaffirms Their Hold Rating on Fate Therapeutics (FATE)